JiuZhou Pharma Industrial Science Park is dedicated to the upstream and downstream of the innovative drug industry chain and CDMO preclinical services. At the same time, it extends across the full life science and healthcare spectrum, with a particular focus on regenerative medicine materials, as well as peptides, medical aesthetics, and broader wellness sectors. The park provides tenant enterprises with R&D testing and incubation, along with comprehensive business support.

In the presence of distinguished guests, Ms. Hua Lirong, Chairwoman of JiuZhou Pharma, together with leaders from Hangzhou Pharma Port and Hangzhou Meili Cloud City, jointly inaugurated the park. Following the ceremony, the three parties signed a co-construction agreement to establish an open and collaborative industrial platform, strengthening the park’s technological core and industrial foundation.

Located at the heart of Hangzhou Pharma Port Town in Qiantang District—part of Zhejiang’s “Ten Thousand Mu, One Hundred Billion” new bio-pharmaceutical industry platform—the park enjoys a prime position with seamless access to Shanghai, Ningbo, and Jiaxing-Shaoxing. Covering 69 mu (about 46,000 m²) with a total floor area of 163,000 m², it integrates healthcare and pharmaceutical R&D and manufacturing, while deeply blending in technology, finance, and cultural creativity. Guided by the concept of “entrepreneurship and living without leaving the park,” it is designed as a vibrant “micro-city” ecosystem, enabling enterprises to focus on growth while talents thrive in both career and lifestyle.

With the park now in operation, JiuZhou Pharma will further leverage its extensive resources and strong influence in pharmaceuticals and life sciences to attract more high-quality innovative drug enterprises and talents. By enhancing the “R&D–manufacturing–services” full industry chain and forming a synergistic cluster effect, the park will empower pharmaceutical and healthcare innovation and incubation. At the same time, it will accelerate breakthroughs and commercialization in regenerative medicine materials, expand the regenerative medicine and wellness industries, and inject new momentum into the region’s high-quality economic growth.

JiuZhou Pharma Industrial Science Park is dedicated to the upstream and downstream of the innovative drug industry chain and CDMO preclinical services. At the same time, it extends across the full life science and healthcare spectrum, with a particular focus on regenerative medicine materials, as well as peptides, medical aesthetics, and broader wellness sectors. The park provides tenant enterprises with R&D testing and incubation, along with comprehensive business support.

In the presence of distinguished guests, Ms. Hua Lirong, Chairwoman of JiuZhou Pharma, together with leaders from Hangzhou Pharma Port and Hangzhou Meili Cloud City, jointly inaugurated the park. Following the ceremony, the three parties signed a co-construction agreement to establish an open and collaborative industrial platform, strengthening the park’s technological core and industrial foundation.

Located at the heart of Hangzhou Pharma Port Town in Qiantang District—part of Zhejiang’s “Ten Thousand Mu, One Hundred Billion” new bio-pharmaceutical industry platform—the park enjoys a prime position with seamless access to Shanghai, Ningbo, and Jiaxing-Shaoxing. Covering 69 mu (about 46,000 m²) with a total floor area of 163,000 m², it integrates healthcare and pharmaceutical R&D and manufacturing, while deeply blending in technology, finance, and cultural creativity. Guided by the concept of “entrepreneurship and living without leaving the park,” it is designed as a vibrant “micro-city” ecosystem, enabling enterprises to focus on growth while talents thrive in both career and lifestyle.

With the park now in operation, JiuZhou Pharma will further leverage its extensive resources and strong influence in pharmaceuticals and life sciences to attract more high-quality innovative drug enterprises and talents. By enhancing the “R&D–manufacturing–services” full industry chain and forming a synergistic cluster effect, the park will empower pharmaceutical and healthcare innovation and incubation. At the same time, it will accelerate breakthroughs and commercialization in regenerative medicine materials, expand the regenerative medicine and wellness industries, and inject new momentum into the region’s high-quality economic growth.

JiuZhou Pharma Industrial Science Park is dedicated to the upstream and downstream of the innovative drug industry chain and CDMO preclinical services. At the same time, it extends across the full life science and healthcare spectrum, with a particular focus on regenerative medicine materials, as well as peptides, medical aesthetics, and broader wellness sectors. The park provides tenant enterprises with R&D testing and incubation, along with comprehensive business support.

In the presence of distinguished guests, Ms. Hua Lirong, Chairwoman of JiuZhou Pharma, together with leaders from Hangzhou Pharma Port and Hangzhou Meili Cloud City, jointly inaugurated the park. Following the ceremony, the three parties signed a co-construction agreement to establish an open and collaborative industrial platform, strengthening the park’s technological core and industrial foundation.

Located at the heart of Hangzhou Pharma Port Town in Qiantang District—part of Zhejiang’s “Ten Thousand Mu, One Hundred Billion” new bio-pharmaceutical industry platform—the park enjoys a prime position with seamless access to Shanghai, Ningbo, and Jiaxing-Shaoxing. Covering 69 mu (about 46,000 m²) with a total floor area of 163,000 m², it integrates healthcare and pharmaceutical R&D and manufacturing, while deeply blending in technology, finance, and cultural creativity. Guided by the concept of “entrepreneurship and living without leaving the park,” it is designed as a vibrant “micro-city” ecosystem, enabling enterprises to focus on growth while talents thrive in both career and lifestyle.

With the park now in operation, JiuZhou Pharma will further leverage its extensive resources and strong influence in pharmaceuticals and life sciences to attract more high-quality innovative drug enterprises and talents. By enhancing the “R&D–manufacturing–services” full industry chain and forming a synergistic cluster effect, the park will empower pharmaceutical and healthcare innovation and incubation. At the same time, it will accelerate breakthroughs and commercialization in regenerative medicine materials, expand the regenerative medicine and wellness industries, and inject new momentum into the region’s high-quality economic growth.